go grey glp 1 Glucagon-like peptide receptor agonists and cancer risk: the good, the bad and the unknown The growing availability of compounded

Get a DEXA Scan at Baseline and at 6 Months Knowing your starting body composition lets you measure actual lean-mass change instead of guessing

Retatrutide is an investigational triple agonist (GIP, GLP-1, and glucagon receptor) not yet approved by the MHRA or EMA, and should only be used within regulated clinical trials or authorised supply channels

Exenatide, the first GLP-1 receptor agonist, was approved in 2005, followed by the development of extended-release versions such as liraglutide and semaglutide (Furman 2012)

One innovative approach we offer involves therapies based on GLP-1, or glucagon-like peptide-1a hormone naturally produced by your body, primarily in the intestine, after you eat